A Randomized, Double-Blind, Placebo-Controlled, Ascending One-Day (Single and Divided Dose) Safety, Tolerability, and Pharmacokinetic Study of EDP-788 in Healthy Adult Volunteers

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Ascending One-Day (Single and Divided Dose) Safety, Tolerability, and Pharmacokinetic Study of EDP-788 in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2015

At a glance

  • Drugs EDP 788 (Primary)
  • Indications Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Streptococcal infections; Vancomycin-resistant enterococcal infections
  • Focus Adverse reactions
  • Sponsors Enanta Pharmaceuticals
  • Most Recent Events

    • 08 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Jul 2014 Planned End Date changed from 1 Jun 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
    • 13 Jan 2014 Status changed from not yet recruiting to recruiting, according to an Enanta Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top